UnknownNot Applicable

Investigating the Diagnostic Potential of Tear Proteins in Cancer - A Pilot Study

United States500 participantsStarted 2021-08-25

Plain-language summary

This Pilot Study is to investigate the tear proteins in a multitude of cancer types and indulge in biomarker discovery to manufacture simple, accurate, and novel tear-based diagnostic tests.

Who can participate

Age range18 Years – 100 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * 18-100 years of age * Presenting for the evaluation of an abnormal exam or test (mammogram, ultrasound, MRI, PET, etc.) * Presenting for the evaluation of a palpable lump or mass * Presenting with a mass may be pre or post-biopsy/diagnostic as long as there is a portion of the mass remaining. * Have been diagnosed but have not received treatment Exclusion Criteria: * Less than 18 years of age OR more than 100 years of age * Concurrent eye infection or trauma * Acute conjunctivitis

What they're measuring

Identify Cancer-related Biomarkers

Timeframe: Dec 2023

Trial details

NCT IDNCT05223218

SponsorNamida Lab

Sponsor typeINDUSTRY

Study typeOBSERVATIONAL

Primary completion2023-11

View on ClinicalTrials.gov More Breast Cancer trials